AppLovin 3Q26 Business Update: No Notes
AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.
AppLovin’s Q3 revenue rose 55% year over year as AXON model gains expanded margins, while ad take-rate compression remains the key competitive risk.
$CRWV has ~$10bn of unsecured HY notes, all yielding 14-15%. There’s also another ~$11bn of converts. That’s ~$21bn of unsecured claims, sitting behind the secured debt that funds the GPUs. Here's the latest market pricing on the HY notes (converts excluded): https://t.co/vVxKgKVCRc
Who had Hyperscalers accelerating to fastest growth rates since Covid at the same time Anthropic massively decelerates on their bingo card for 3Q26? I think very few 3-6mo ago, but here we are! $MSFT $GOOG $AMZN
The asset base is too large and diversified to ever underwrite loan by loan. The thesis is that the private credit apocalypse is exaggerated, $OWL became the poster child given its reliance on the HNW channel, and the market is assigning far too little value to its non-credit assets and durable fee-generating franchise.
@FrenchV33921 Already there with $CRWV and $IREN IS $NBIS worse?
@sidecarcap This is exactly what I think is happening with $SLM $KSPI and maybe $YB. $KNSL too
@Pembrokestcap But isn’t $OWL reputation, and by extension their ability to raise capital, permanently impaired? Who cares if they own valuable GP stakes and real estate businesses that never tapped the high-net-worth channel? Isn’t the entire franchise structurally compromised?
Shorts that aren't actually that overvalued (a 10+15% grower trading at 30x earnings can be overvalued, but still easily trade to 40-50x). Sizing is very important. Stuff like $CBA, $WDFC, $WMT, $WING have been some of my biggest winners this year with no catalyst.
Amazon’s AWS grew 39.3% with roughly 39% margins, while retail unit growth and lower cost to serve expand its delivery network’s reach.
Intel's Q3 2026 results were hit by memory costs and an Israel shutdown, but enterprise AI inference could lift CPU demand as server…
Telkom Indonesia trades at 9x earnings and an 11% yield as MSCI-driven selling obscures telecom consolidation, price increases and…
Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…
Delta Air Lines' premium, loyalty and ancillary businesses generate 61% of revenue as cash flow supports debt reduction despite fuel and…
Microsoft rose 6.7% to a $555.80 record after Q1 FY27, with profitable growth and free cash flow reinforcing investor confidence in its AI…
GPC’s NAPA commercial sales grew 4% in Q3, trailing AutoZone and O’Reilly as freight, fuel and rent cut North American Automotive margins…
AMSC and Datadog will be fine, while SiTime is worth a closer look.
Intuit CEO Sasan Goodarzi discusses using AI to turn accountants from customer-acquisition partners into customers, alongside QuickBooks,…
DigitalOcean reported Q3 revenue up 40% to $321 million and lifted Q4 guidance above consensus, while GPU and data-center expansion cut…
Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…
L3Harris booked $19.3 billion of Q3 orders, lifting backlog to $53.2 billion, raised FY26 guidance and cut its 2028 free-cash-flow target…
Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…
David Orr describes running Militia Capital’s roughly 500-stock long-short portfolio, using expected value, correlation and factor…
Coupang expects Product Commerce margins to return to pre-data incident levels by mid-2027 as customer spending recovers and Taiwan…
Novo Nordisk beat Q3 consensus as Wegovy pill sales reached DKK 5.4bn, raised 2026 guidance again and reported DKK 79.2bn revenue.
Shopify's 3Q 2026 GMV grew 30% FX-neutral, reaching 46% of Amazon retail GMV after merchants captured nearly half of incremental U.S.
Eli Lilly uses AI-driven drug discovery and its research scale to accelerate molecule development and broaden its product pipeline.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.